Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us
  • Log in to HL Account

Cel-Sci Corp (CVM) Common Stock USD0.001

Sell:$12.30 Buy:$13.19 Change: $0.16 (1.27%)
Market closed |  Prices as at close on 25 September 2020 | Switch to live prices |
Sell:$12.30
Buy:$13.19
Change: $0.16 (1.27%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 25 September 2020 | Switch to live prices |
Sell:$12.30
Buy:$13.19
Change: $0.16 (1.27%)
Market closed |  Prices as at close on 25 September 2020 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for treatment of certain head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus and human papillomavirus co-infected patients and Ligand Epitope Antigen Presentation System (L.E.A.P.S.) technology, with over two investigational therapies, LEAPS-H1N1-DC, a product candidate under development for treatment of pandemic influenza in hospitalized patients, and CEL-2000 and CEL-4000, vaccine product candidates under development for treatment of rheumatoid arthritis.

Contact details

Address:
8229 Boone Blvd Ste 802
VIENNA
22182-2634
United States
Telephone:
+1 (703) 5069460
Website:
www.cel-sci.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CVM
ISIN:
US1508376076
Market cap:
$481.64 million
Shares in issue:
38.62 million
Sector:
Biotechnology
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Geert Kersten
    Chief Executive Officer, Treasurer, Director
  • Patricia Prichep
    Senior Vice President - Operations, Corporate Secretary
  • John Cipriano
    Senior Vice President - Regulatory Affairs
  • Daniel Zimmerman
    Senior Vice President - Research, Cellular Immunology
  • Eyal Talor
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.